ANI Pharmaceuticals (ANIP)
(Delayed Data from NSDQ)
$63.93 USD
+0.58 (0.92%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $63.93 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth B Momentum A VGM
Fundamental Charts
About Market Cap
As of the previous market close, ANI Pharmaceuticals, Inc. has a market cap of $1.37B, which represents its share price of $63.35 multiplied by its outstanding shares number of 21.66M. As a small-cap company, ANIP's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ANIP 63.93 +0.58(0.92%)
Will ANIP be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANIP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIP
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
ANIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Q2 Release
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q2 Earnings and Revenue Estimates
Will ANI (ANIP) Beat Estimates Again in Its Next Earnings Report?
Other News for ANIP
ANI Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 8, 2025, at 8:30 ...
ANIP Faces Setback in Legal Dispute Over Royalties
ANI Pharmaceuticals: Classic Case Of Capital Intensive Growth Hampering Value
Optimistic Growth Potential for ANI Pharmaceuticals Despite Challenges in DME Treatment
ANI Pharmaceuticals (ANIP) Shares Drop Following Clinical Trial Results